Global Mycoplasma Testing Market

1 INTRODUCTION OF GLOBAL MYCOPLASMA TESTINGMARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL MYCOPLASMA TESTINGMARKETOUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework
5 GLOBAL MYCOPLASMA TESTING MARKET, BY END USER
5.1 Pharmaceutical and Biotechnology Companies
5.2 Contract Research Organizations
5.3 Academic Research Institutes
5.4 Cell Banks
5.5 Other End Users

6 GLOBAL MYCOPLASMA TESTING MARKET, BY APPLICATION
6.1 Cell Line Testing
6.2 Virus Testing
6.3 End-Of-Production Cell Testing
6.4 Other Applications

7 GLOBAL MYCOPLASMA TESTING MARKET, BY TECHNIQUE
7.1 PCR
7.2 Elisa
7.3 Direct Assays
7.4 Indirect Assays
7.5 Dna Staining
7.6 Microbial Culture Techniques
7.7 Enzymatic Methods

8 GLOBAL MYCOPLASMA TESTING MARKET, BY PRODUCT
8.1 Kits and Reagents
8.1.1 PCR Assays
8.1.2 Nucleic Acid Detection Kits
8.1.3 Elimination Kits & Reagents
8.1.4 Stains
8.1.5 Standards & Controls
8.1.6 Other Kits & Reagents
8.2 Instruments
8.3 Services
9 GLOBAL MYCOPLASMA TESTINGMARKET, BY GEOGRAPHY
9.1 Overview
9.2 North AmericaRegional Market Estimates and Forecasts, 2012 - 2025
9.2.1 U.S.
9.2.2 Canada
9.2.3 Mexico
9.3 EuropeRegional Market Estimates and Forecasts, 2012 - 2025
9.3.1 Germany
9.3.2 U.K.
9.3.3 France
9.3.4 Rest of Europe
9.4 Asia PacificRegional Market Estimates and Forecasts, 2012 - 2025
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Rest of Asia Pacific
9.5 Latin AmericaRegional Market Estimates and Forecasts, 2012 - 2025
9.5.1 Brazil
9.5.2 Argentina
9.6 Rest of the WorldRegional Market Estimates and Forecasts, 2012 - 2025

10 GLOBAL MYCOPLASMA TESTINGMARKETCOMPETITIVE LANDSCAPE
10.1 Overview
10.2 Company Market Share
10.3 Vendor Landscape
10.4 Key Development Strategies

11 COMPANY PROFILES
11.1 Charles River Laboratories International, Inc.
11.1.1 Overview
11.1.2 Financial Performance
11.1.3 Product Outlook
11.1.4 Key Developments

11.2 Merck KGaA
11.2.1 Overview
11.2.2 Financial Performance
11.2.3 Product Outlook
11.2.4 Key Developments

11.3 Lonza Group Ltd.
11.3.1 Overview
11.3.2 Financial Performance
11.3.3 Product Outlook
11.3.4 Key Developments

11.4 Roche Diagnostics (Division of F. Hoffman-LA Roche Ltd.)
11.4.1 Overview
11.4.2 Financial Performance
11.4.3 Product Outlook
11.4.4 Key Developments

11.5 SGS S.A.
11.5.1 Overview
11.5.2 Financial Performance
11.5.3 Product Outlook
11.5.4 Key Developments

11.6 Thermo Fisher Scientific Inc.
11.6.1 Overview
11.6.2 Financial Performance
11.6.3 Product Outlook
11.6.4 Key Developments

11.7 American Type Culture Collection
11.7.1 Overview
11.7.2 Financial Performance
11.7.3 Product Outlook
11.7.4 Key Developments

11.8 Biounique Testing Laboratories Inc.
11.8.1 Overview
11.8.2 Financial Performance
11.8.3 Product Outlook
11.8.4 Key Developments

11.9 Invivogen
11.9.1 Overview
11.9.2 Financial Performance
11.9.3 Product Outlook
11.9.4 Key Developments

11.10 Promocell GmbH
11.10.1 Overview
11.10.2 Financial Performance
11.10.3 Product Outlook
11.10.4 Key Developments

11.11 Biological Industries Israel Beit Haemek Ltd.
11.11.1 Overview
11.11.2 Financial Performance
11.11.3 Product Outlook
11.11.4 Key Developments

11.12 Wuxi Apptec
11.12.1 Overview
11.12.2 Financial Performance
11.12.3 Product Outlook
11.12.4 Key Developments

11.13 NorgenBiotek Corporation
11.13.1 Overview
11.13.2 Financial Performance
11.13.3 Product Outlook
11.13.4 Key Developments

12 Appendix
12.1 Related Reports